Quantcast

Latest Nephrotic syndrome Stories

2014-09-11 08:28:06

CAMBRIDGE, Mass., Sept. 11, 2014 /PRNewswire-USNewswire/ -- Claritas Genomics, a clinical laboratory serving the DNA-based diagnostic testing needs of children's hospitals, announced the availability of a next-generation sequencing assay that investigates 28 genes that represent single-gene causes of pediatric steroid-resistant Nephrotic Syndrome. The assay was developed in collaboration with a laboratory at Boston Children's Hospital that has been studying the underlying genetic...

2014-08-14 16:27:16

- Creates a diversified, high-growth therapeutic portfolio, capable of delivering substantial, sustainable value for shareholders DUBLIN, Aug. 14, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it has completed its acquisition of Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) in a cash and stock transaction valued at approximately $5.8 billion. The acquisition is expected to be immediately accretive to Mallinckrodt's...

2014-07-24 08:34:45

Net Sales $279 Million; Increase of 42% over Prior Year Non-GAAP Results ANAHEIM, Calif., July 24, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the second quarter ended June 30, 2014. Three Months Ended Three Months Ended 06/30/14 06/30/13 Percentage Change --------------------- --------------------- ----------------- GAAP Net Sales...

2014-04-21 08:26:07

- Clinical results appear to correlate with reduction in anti-PLA2R antibodies ANAHEIM, Calif., April 21, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that results from an investigator-initiated clinical study involving two major academic research centers examining the dosing and effectiveness of H.P. Acthar® Gel (repository corticotropin) in 20 patients with nephrotic syndrome due to idiopathic membranous nephropathy (iMN) have been published in the...

2014-01-31 10:46:34

In patients with a frequently-relapsing form of kidney disease, relapses decreased approximately five-fold for at least one year after patients took a single dose of rituximab, an antibody that targets the immune system and is often used to treat immune disorders such as lymphoma and arthritis. The findings, which will appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), suggest that this drug may provide considerable benefits for patients. For most...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related